<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01958671</url>
  </required_header>
  <id_info>
    <org_study_id>8835-003</org_study_id>
    <secondary_id>2013-002519-90</secondary_id>
    <secondary_id>B1521022</secondary_id>
    <nct_id>NCT01958671</nct_id>
  </id_info>
  <brief_title>A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)</brief_title>
  <official_title>A Phase 3, Randomized, Double-blind, Placebo-controlled, 26-week Multicenter Study With a 26-Week Extension to Evaluate the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will evaluate the efficacy and safety of ertugliflozin monotherapy in the
      treatment of participants with type 2 diabetes mellitus (T2DM) and inadequate glycemic
      control on diet and exercise. This trial consists of a run-in period of 3 to 11 weeks, a
      26-week placebo-controlled treatment period (Phase A), and a 26-week active treatment period
      (Phase B). The primary hypotheses of the trial are that at Week 26, the mean reduction from
      baseline in hemoglobin A1c (A1C) for 15 mg ertugliflozin is greater than that for placebo and
      the mean reduction from baseline in A1C for 5 mg ertugliflozin is greater than that for
      placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 9, 2013</start_date>
  <completion_date type="Actual">July 28, 2016</completion_date>
  <primary_completion_date type="Actual">July 28, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline In A1C at Week 26</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>A1C is measured as percent. The change from baseline is the Week 26 A1C percent minus the Week 0 A1C percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing An Adverse Event (AE)</measure>
    <time_frame>Up to 54 weeks (including 2 weeks following last dose)</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Discontinuing Study Treatment Due to an AE</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FPG at Week 26</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>The change from baseline is the Week 26 FPG minus the Week 0 FPG. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of glycemic rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Week 26</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>The change from baseline is the Week 26 body weight minus the Week 0 body weight. Data presented exclude data following the initiation of rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With A1C &lt;7% (&lt;53 mmol/Mol) at Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>A1C is measured as percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline 2-hour Post-prandial Glucose (2-hr PPG) Level</measure>
    <time_frame>Baseline</time_frame>
    <description>Laboratory measurements were performed 120 minutes following the start of the administration of the meal for the Mixed Meal Tolerance Test (MMTT). Change from baseline in 2-hr PPG level at Week 26 data are presented in the following outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 2-hr PPG at Week 26</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>The change from baseline is the Week 26 2-hr PPG minus the Week 0 2-hr PPG. Laboratory measurements were performed 120 minutes following the start of the administration of the meal for the MMTT. Data presented exclude data following the initiation of rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Sitting Systolic Blood Pressure (SBP)</measure>
    <time_frame>Baseline</time_frame>
    <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Change from baseline in SBP at Week 26 data are presented in the following outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SBP at Week 26</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>The change from baseline is the Week 26 SBP minus the Week 0 SBP. Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Data presented exclude data following the initiation of rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Sitting Diastolic Blood Pressure (DBP)</measure>
    <time_frame>Baseline</time_frame>
    <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Change from baseline in DBP at Week 26 data are presented in the following outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DBP at Week 26</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>The change from baseline is the Week 26 DBP minus the Week 0 DBP. Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Data presented exclude data following the initiation of rescue therapy.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">461</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Ertugliflozin 5 mg/Ertugliflozin 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase A: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin 15 mg/Ertugliflozin 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase A: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Metformin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Phase A: Placebo to ertugliflozin administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Participants not rescued with open-label metformin in Phase A will also receive blinded metformin up to twice daily for 26 weeks in addition to placebo. Participants rescued with metformin in Phase A will continue to receive open-label metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin 5 mg</intervention_name>
    <description>One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).</description>
    <arm_group_label>Ertugliflozin 5 mg/Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 15 mg/Ertugliflozin 15 mg</arm_group_label>
    <other_name>MK-8835</other_name>
    <other_name>PF-04971729</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin 10 mg</intervention_name>
    <description>One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).</description>
    <arm_group_label>Ertugliflozin 15 mg/Ertugliflozin 15 mg</arm_group_label>
    <other_name>MK-8835</other_name>
    <other_name>PF-04971729</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Ertugliflozin</intervention_name>
    <description>One placebo tablet matching the ertugliflozin 5 mg tablet and/or 1 placebo tablet matching the ertugliflozin 10 mg tablet per day taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).</description>
    <arm_group_label>Ertugliflozin 5 mg/Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>Placebo/Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>500 mg (1 tablet) in the morning and 500 mg (1 tablet) in the evening for 2 weeks, 1000 mg (2 tablets 500 mg) in the morning and 500 mg (1 tablet) in the evening for 2 weeks and 1000 mg (2 tablets 500 mg) in the morning and 1000 mg (2 tablets 500 mg) in the evening, thereafter.</description>
    <arm_group_label>Ertugliflozin 5 mg/Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 15 mg/Ertugliflozin 15 mg</arm_group_label>
    <arm_group_label>Placebo/Metformin</arm_group_label>
    <other_name>Glucophage XR, Carbophage SR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, Diaformin, Siofor and Metfogamma.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Metformin</intervention_name>
    <description>1 tablet in the morning and 1 tablet in the evening for 2 weeks, 2 tablets in the morning and 1 tablet in the evening for 2 weeks and 2 tablets in the morning and 2 tablets in the evening, thereafter.</description>
    <arm_group_label>Ertugliflozin 5 mg/Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 15 mg/Ertugliflozin 15 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <description>Dosing and titration of glimepiride as rescue therapy was determined by the investigator.</description>
    <arm_group_label>Ertugliflozin 5 mg/Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 15 mg/Ertugliflozin 15 mg</arm_group_label>
    <arm_group_label>Placebo/Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of T2DM in accordance to American Diabetes Association guidelines

          -  Participants with no prior allowable oral anti-hyperglycemic agents (AHA) for at least
             8 weeks prior to study participation or participants on a single allowable oral AHA at
             the start of study participation

          -  Participants on a single allowable AHA must be willing to discontinue this medication
             at the Screening Visit (S2) and remain off this medication for the duration of the
             trial. Allowable oral AHAs for discontinuation are metformin, sulfonylureas,
             dipeptidyl peptidase-4 (DPP-4) inhibitors, glinides or alpha-glucosidase inhibitors.

        Exclusion Criteria:

          -  History of myocardial infarction, unstable angina, arterial revascularization, stroke,
             transient ischemic attack, or New York Heart Association (NYHA) functional class
             III-IV heart failure within 3 months of study participation

          -  A clinically significant electrocardiogram abnormality

          -  A history of malignancy ≤5 years prior to study participation, except for adequately
             treated basal or squamous cell skin cancer or in situ cervical cancer

          -  A known hypersensitivity or intolerance to any sodium-glucose co-transporter 2 (SGLT2)
             inhibitor or metformin

          -  On a blood pressure or lipid altering medication that have not been on a stable dose
             for at least 4 weeks prior to study participation

          -  A surgical procedure within 4 weeks prior to study participation or planned major
             surgery during the trial

          -  Donation of blood or blood products within 6 weeks of study participation or plans to
             donate blood or blood products at any time during the trial

          -  Pregnant or breast-feeding, or is expecting to conceive during the trial, including 14
             days following the last dose of study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>South Africa</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Terra SG, Focht K, Davies M, Frias J, Derosa G, Darekar A, Golm G, Johnson J, Saur D, Lauring B, Dagogo-Jack S. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017 May;19(5):721-728. doi: 10.1111/dom.12888. Epub 2017 Feb 22.</citation>
    <PMID>28116776</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2013</study_first_submitted>
  <study_first_submitted_qc>October 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2013</study_first_posted>
  <results_first_submitted>July 14, 2017</results_first_submitted>
  <results_first_submitted_qc>September 1, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 29, 2017</results_first_posted>
  <last_update_submitted>September 1, 2017</last_update_submitted>
  <last_update_submitted_qc>September 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ertugliflozin 5 mg/Ertugliflozin 5 mg</title>
          <description>Phase A: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.</description>
        </group>
        <group group_id="P2">
          <title>Ertugliflozin 15 mg/Ertugliflozin 15 mg</title>
          <description>Phase A: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.</description>
        </group>
        <group group_id="P3">
          <title>Placebo/Metformin</title>
          <description>Phase A: Placebo to ertugliflozin administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Participants not rescued with open-label metformin in Phase A will also receive blinded metformin up to twice daily for 26 weeks in addition to placebo. Participants rescued with metformin in Phase A will continue to receive open-label metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="156"/>
                <participants group_id="P2" count="152"/>
                <participants group_id="P3" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
                <participants group_id="P2" count="128"/>
                <participants group_id="P3" count="121"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Excluded medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hyperglycemia</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study site terminated by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant moved</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ertugliflozin 5 mg/Ertugliflozin 5 mg</title>
          <description>Phase A: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.</description>
        </group>
        <group group_id="B2">
          <title>Ertugliflozin 15 mg/Ertugliflozin 15 mg</title>
          <description>Phase A: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.</description>
        </group>
        <group group_id="B3">
          <title>Placebo/Metformin</title>
          <description>Phase A: Placebo to ertugliflozin administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Participants not rescued with open-label metformin in Phase A will also receive blinded metformin up to twice daily for 26 weeks in addition to placebo. Participants rescued with metformin in Phase A will continue to receive open-label metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="156"/>
            <count group_id="B2" value="152"/>
            <count group_id="B3" value="153"/>
            <count group_id="B4" value="461"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="156"/>
                    <count group_id="B2" value="152"/>
                    <count group_id="B3" value="153"/>
                    <count group_id="B4" value="461"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.8" spread="11.4"/>
                    <measurement group_id="B2" value="56.2" spread="10.8"/>
                    <measurement group_id="B3" value="56.1" spread="10.9"/>
                    <measurement group_id="B4" value="56.4" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="156"/>
                    <count group_id="B2" value="152"/>
                    <count group_id="B3" value="153"/>
                    <count group_id="B4" value="461"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="200"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c (A1C)</title>
          <population>All randomized participants who received at least 1 dose of study treatment and had baseline A1C measurement.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="155"/>
                    <count group_id="B2" value="151"/>
                    <count group_id="B3" value="153"/>
                    <count group_id="B4" value="459"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.16" spread="0.88"/>
                    <measurement group_id="B2" value="8.35" spread="1.12"/>
                    <measurement group_id="B3" value="8.11" spread="0.92"/>
                    <measurement group_id="B4" value="8.21" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting plasma glucose (FPG)</title>
          <population>All randomized participants who received at least 1 dose of study treatment and had baseline FPG measurement.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="151"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="150"/>
                    <count group_id="B4" value="450"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="180.9" spread="48.5"/>
                    <measurement group_id="B2" value="179.1" spread="48.2"/>
                    <measurement group_id="B3" value="180.2" spread="45.8"/>
                    <measurement group_id="B4" value="180.1" spread="47.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated glomerular filtration rate (eGFR)</title>
          <units>mL/min/1.75m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="156"/>
                    <count group_id="B2" value="152"/>
                    <count group_id="B3" value="153"/>
                    <count group_id="B4" value="461"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88.5" spread="18.4"/>
                    <measurement group_id="B2" value="88.3" spread="18.0"/>
                    <measurement group_id="B3" value="86.2" spread="19.4"/>
                    <measurement group_id="B4" value="87.7" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight</title>
          <units>Kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="156"/>
                    <count group_id="B2" value="152"/>
                    <count group_id="B3" value="153"/>
                    <count group_id="B4" value="461"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94.0" spread="25.4"/>
                    <measurement group_id="B2" value="90.6" spread="18.3"/>
                    <measurement group_id="B3" value="94.2" spread="25.2"/>
                    <measurement group_id="B4" value="92.9" spread="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline In A1C at Week 26</title>
        <description>A1C is measured as percent. The change from baseline is the Week 26 A1C percent minus the Week 0 A1C percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>Analysis population consisted of all randomized participants who received at least 1 dose of study treatment and had a baseline A1C measurement or at least 1 post-randomization A1C measurement subsequent to at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg</title>
            <description>Participants received ertugliflozin 5 mg once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg</title>
            <description>Participants received ertugliflozin 15 mg once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo to ertugliflozin once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline In A1C at Week 26</title>
          <description>A1C is measured as percent. The change from baseline is the Week 26 A1C percent minus the Week 0 A1C percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.</description>
          <population>Analysis population consisted of all randomized participants who received at least 1 dose of study treatment and had a baseline A1C measurement or at least 1 post-randomization A1C measurement subsequent to at least 1 dose of study treatment.</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" lower_limit="-0.95" upper_limit="-0.63"/>
                    <measurement group_id="O2" value="-0.96" lower_limit="-1.12" upper_limit="-0.80"/>
                    <measurement group_id="O3" value="0.20" lower_limit="0.02" upper_limit="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Constrained longitudinal data analysis</method>
            <method_desc>Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.22</ci_lower_limit>
            <ci_upper_limit>-0.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Constrained longitudinal data analysis</method>
            <method_desc>Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.39</ci_lower_limit>
            <ci_upper_limit>-0.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Experiencing An Adverse Event (AE)</title>
        <description>An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy.</description>
        <time_frame>Up to 54 weeks (including 2 weeks following last dose)</time_frame>
        <population>Analysis population consisted of all randomized participants who received at least 1 dose of study treatment. Participants were classified according to randomized treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg/Ertugliflozin 5 mg</title>
            <description>Phase A: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg/Ertugliflozin 15 mg</title>
            <description>Phase A: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Metformin</title>
            <description>Phase A: Placebo to ertugliflozin administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Participants not rescued with open-label metformin in Phase A will also receive blinded metformin up to twice daily for 26 weeks in addition to placebo. Participants rescued with metformin in Phase A will continue to receive open-label metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing An Adverse Event (AE)</title>
          <description>An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy.</description>
          <population>Analysis population consisted of all randomized participants who received at least 1 dose of study treatment. Participants were classified according to randomized treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.1"/>
                    <measurement group_id="O2" value="62.5"/>
                    <measurement group_id="O3" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in percentage</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.1</ci_lower_limit>
            <ci_upper_limit>8.1</ci_upper_limit>
            <estimate_desc>Based on Miettinen &amp; Nurminen method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in percentage</param_type>
            <param_value>-4.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.8</ci_lower_limit>
            <ci_upper_limit>6.6</ci_upper_limit>
            <estimate_desc>Based on Miettinen &amp; Nurminen method.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Discontinuing Study Treatment Due to an AE</title>
        <description>An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy.</description>
        <time_frame>Up to 52 weeks</time_frame>
        <population>Analysis population consisted of all randomized participants who received at least 1 dose of study treatment. Participants were classified according to randomized treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg/Ertugliflozin 5 mg</title>
            <description>Phase A: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg/Ertugliflozin 15 mg</title>
            <description>Phase A: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Metformin</title>
            <description>Phase A: Placebo to ertugliflozin administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Participants not rescued with open-label metformin in Phase A will also receive blinded metformin up to twice daily for 26 weeks in addition to placebo. Participants rescued with metformin in Phase A will continue to receive open-label metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Discontinuing Study Treatment Due to an AE</title>
          <description>An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy.</description>
          <population>Analysis population consisted of all randomized participants who received at least 1 dose of study treatment. Participants were classified according to randomized treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5"/>
                    <measurement group_id="O2" value="3.9"/>
                    <measurement group_id="O3" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in percentage</param_type>
            <param_value>-2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.7</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
            <estimate_desc>Based on Miettinen &amp; Nurminen method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in percentage</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.2</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
            <estimate_desc>Based on Miettinen &amp; Nurminen method.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FPG at Week 26</title>
        <description>The change from baseline is the Week 26 FPG minus the Week 0 FPG. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of glycemic rescue therapy.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>Analysis population consisted of all randomized participants who received at least 1 dose of study treatment and had a baseline FPG measurement or at least 1 post-randomization FPG measurement subsequent to at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg</title>
            <description>Participants received ertugliflozin 5 mg once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg</title>
            <description>Participants received ertugliflozin 15 mg once daily for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo to ertugliflozin once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FPG at Week 26</title>
          <description>The change from baseline is the Week 26 FPG minus the Week 0 FPG. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of glycemic rescue therapy.</description>
          <population>Analysis population consisted of all randomized participants who received at least 1 dose of study treatment and had a baseline FPG measurement or at least 1 post-randomization FPG measurement subsequent to at least 1 dose of study treatment.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.96" lower_limit="-39.85" upper_limit="-28.06"/>
                    <measurement group_id="O2" value="-43.44" lower_limit="-49.39" upper_limit="-37.49"/>
                    <measurement group_id="O3" value="0.57" lower_limit="-6.02" upper_limit="7.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Constrained longitudinal data analysis</method>
            <method_desc>Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-34.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.76</ci_lower_limit>
            <ci_upper_limit>-26.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Constrained longitudinal data analysis</method>
            <method_desc>Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-44.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-52.28</ci_lower_limit>
            <ci_upper_limit>-35.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Week 26</title>
        <description>The change from baseline is the Week 26 body weight minus the Week 0 body weight. Data presented exclude data following the initiation of rescue therapy.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>Analysis population consisted of all randomized participants who received at least 1 dose of study treatment and had a baseline body weight measurement or at least 1 post-randomization body weight measurement subsequent to at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg</title>
            <description>Participants received ertugliflozin 5 mg once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg</title>
            <description>Participants received ertugliflozin 15 mg once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo to ertugliflozin once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Week 26</title>
          <description>The change from baseline is the Week 26 body weight minus the Week 0 body weight. Data presented exclude data following the initiation of rescue therapy.</description>
          <population>Analysis population consisted of all randomized participants who received at least 1 dose of study treatment and had a baseline body weight measurement or at least 1 post-randomization body weight measurement subsequent to at least 1 dose of study treatment.</population>
          <units>Kilograms</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.18" lower_limit="-3.72" upper_limit="-2.63"/>
                    <measurement group_id="O2" value="-3.58" lower_limit="-4.13" upper_limit="-3.02"/>
                    <measurement group_id="O3" value="-1.42" lower_limit="-2.02" upper_limit="-0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Constrained longitudinal data analysis</method>
            <method_desc>Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-1.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.57</ci_lower_limit>
            <ci_upper_limit>-0.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Constrained longitudinal data analysis</method>
            <method_desc>Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.98</ci_lower_limit>
            <ci_upper_limit>-1.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With A1C &lt;7% (&lt;53 mmol/Mol) at Week 26</title>
        <description>A1C is measured as percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.</description>
        <time_frame>Week 26</time_frame>
        <population>Analysis population consisted of all randomized participants who received at least 1 dose of study treatment and had a baseline A1C measurement or at least 1 post-randomization A1C measurement subsequent to at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg</title>
            <description>Participants received ertugliflozin 5 mg once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg</title>
            <description>Participants received ertugliflozin 15 mg once daily for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo to ertugliflozin once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With A1C &lt;7% (&lt;53 mmol/Mol) at Week 26</title>
          <description>A1C is measured as percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.</description>
          <population>Analysis population consisted of all randomized participants who received at least 1 dose of study treatment and had a baseline A1C measurement or at least 1 post-randomization A1C measurement subsequent to at least 1 dose of study treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.2"/>
                    <measurement group_id="O2" value="35.8"/>
                    <measurement group_id="O3" value="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Fixed effects for treatment, prior antihyperglycemic medication, covariates for baseline A1C and baseline eGFR.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.85</ci_lower_limit>
            <ci_upper_limit>6.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Fixed effects for treatment, prior antihyperglycemic medication, covariates for baseline A1C and baseline</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>6.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.46</ci_lower_limit>
            <ci_upper_limit>13.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline 2-hour Post-prandial Glucose (2-hr PPG) Level</title>
        <description>Laboratory measurements were performed 120 minutes following the start of the administration of the meal for the Mixed Meal Tolerance Test (MMTT). Change from baseline in 2-hr PPG level at Week 26 data are presented in the following outcome measure.</description>
        <time_frame>Baseline</time_frame>
        <population>Analysis population consisted of all randomized participants who had a baseline 2-hr PPG measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg</title>
            <description>Participants received ertugliflozin 5 mg once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg</title>
            <description>Participants received ertugliflozin 15 mg once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo to ertugliflozin once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline 2-hour Post-prandial Glucose (2-hr PPG) Level</title>
          <description>Laboratory measurements were performed 120 minutes following the start of the administration of the meal for the Mixed Meal Tolerance Test (MMTT). Change from baseline in 2-hr PPG level at Week 26 data are presented in the following outcome measure.</description>
          <population>Analysis population consisted of all randomized participants who had a baseline 2-hr PPG measurement.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="260.32" spread="76.110"/>
                    <measurement group_id="O2" value="262.91" spread="78.189"/>
                    <measurement group_id="O3" value="256.21" spread="76.917"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 2-hr PPG at Week 26</title>
        <description>The change from baseline is the Week 26 2-hr PPG minus the Week 0 2-hr PPG. Laboratory measurements were performed 120 minutes following the start of the administration of the meal for the MMTT. Data presented exclude data following the initiation of rescue therapy.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>Analysis population consisted of all randomized participants who received at least 1 dose of study treatment and had a baseline 2-hr PPG measurement or at least 1 post-randomization 2-hr PPG measurement subsequent to at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg</title>
            <description>Participants received ertugliflozin 5 mg once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg</title>
            <description>Participants received ertugliflozin 15 mg once daily for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo to ertugliflozin once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 2-hr PPG at Week 26</title>
          <description>The change from baseline is the Week 26 2-hr PPG minus the Week 0 2-hr PPG. Laboratory measurements were performed 120 minutes following the start of the administration of the meal for the MMTT. Data presented exclude data following the initiation of rescue therapy.</description>
          <population>Analysis population consisted of all randomized participants who received at least 1 dose of study treatment and had a baseline 2-hr PPG measurement or at least 1 post-randomization 2-hr PPG measurement subsequent to at least 1 dose of study treatment.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-64.15" lower_limit="-74.34" upper_limit="-53.96"/>
                    <measurement group_id="O2" value="-62.45" lower_limit="-72.91" upper_limit="-51.98"/>
                    <measurement group_id="O3" value="4.88" lower_limit="-6.15" upper_limit="15.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Constrained longitudinal data analysis</method>
            <method_desc>Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-69.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-83.24</ci_lower_limit>
            <ci_upper_limit>-54.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Constrained longitudinal data analysis</method>
            <method_desc>Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-67.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-81.73</ci_lower_limit>
            <ci_upper_limit>-52.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Sitting Systolic Blood Pressure (SBP)</title>
        <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Change from baseline in SBP at Week 26 data are presented in the following outcome measure.</description>
        <time_frame>Baseline</time_frame>
        <population>Analysis population consisted of all randomized participants who had a baseline SBP measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg</title>
            <description>Participants received ertugliflozin 5 mg once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg</title>
            <description>Participants received ertugliflozin 15 mg once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo to ertugliflozin once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Sitting Systolic Blood Pressure (SBP)</title>
          <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Change from baseline in SBP at Week 26 data are presented in the following outcome measure.</description>
          <population>Analysis population consisted of all randomized participants who had a baseline SBP measurement.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.49" spread="13.511"/>
                    <measurement group_id="O2" value="129.67" spread="14.208"/>
                    <measurement group_id="O3" value="129.80" spread="14.464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SBP at Week 26</title>
        <description>The change from baseline is the Week 26 SBP minus the Week 0 SBP. Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Data presented exclude data following the initiation of rescue therapy.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>Analysis population consisted of all randomized participants who received at least 1 dose of study treatment and had a baseline SBP measurement or at least 1 post-randomization SBP measurement subsequent to at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg</title>
            <description>Participants received ertugliflozin 5 mg once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg</title>
            <description>Participants received ertugliflozin 15 mg once daily for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo to ertugliflozin once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SBP at Week 26</title>
          <description>The change from baseline is the Week 26 SBP minus the Week 0 SBP. Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Data presented exclude data following the initiation of rescue therapy.</description>
          <population>Analysis population consisted of all randomized participants who received at least 1 dose of study treatment and had a baseline SBP measurement or at least 1 post-randomization SBP measurement subsequent to at least 1 dose of study treatment.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.54" lower_limit="-7.32" upper_limit="-3.76"/>
                    <measurement group_id="O2" value="-3.93" lower_limit="-5.74" upper_limit="-2.12"/>
                    <measurement group_id="O3" value="-2.22" lower_limit="-4.30" upper_limit="-0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>Constrained longitudinal data analysis</method>
            <method_desc>Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-3.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.98</ci_lower_limit>
            <ci_upper_limit>-0.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.213</p_value>
            <method>Constrained longitudinal data analysis</method>
            <method_desc>Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-1.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.40</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Sitting Diastolic Blood Pressure (DBP)</title>
        <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Change from baseline in DBP at Week 26 data are presented in the following outcome measure.</description>
        <time_frame>Baseline</time_frame>
        <population>Analysis population consisted of all randomized participants who had a baseline DBP measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg</title>
            <description>Participants received ertugliflozin 5 mg once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg</title>
            <description>Participants received ertugliflozin 15 mg once daily for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo to ertugliflozin once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Sitting Diastolic Blood Pressure (DBP)</title>
          <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Change from baseline in DBP at Week 26 data are presented in the following outcome measure.</description>
          <population>Analysis population consisted of all randomized participants who had a baseline DBP measurement.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.46" spread="8.117"/>
                    <measurement group_id="O2" value="78.53" spread="7.714"/>
                    <measurement group_id="O3" value="78.13" spread="7.458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DBP at Week 26</title>
        <description>The change from baseline is the Week 26 DBP minus the Week 0 DBP. Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Data presented exclude data following the initiation of rescue therapy.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>Analysis population consisted of all randomized participants who received at least 1 dose of study treatment and had a baseline DBP measurement or at least 1 post-randomization DBP measurement subsequent to at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg</title>
            <description>Participants received ertugliflozin 5 mg once daily for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg</title>
            <description>Participants received ertugliflozin 15 mg once daily for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo to ertugliflozin once daily for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DBP at Week 26</title>
          <description>The change from baseline is the Week 26 DBP minus the Week 0 DBP. Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Data presented exclude data following the initiation of rescue therapy.</description>
          <population>Analysis population consisted of all randomized participants who received at least 1 dose of study treatment and had a baseline DBP measurement or at least 1 post-randomization DBP measurement subsequent to at least 1 dose of study treatment.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.52" lower_limit="-3.65" upper_limit="-1.40"/>
                    <measurement group_id="O2" value="-1.10" lower_limit="-2.24" upper_limit="0.05"/>
                    <measurement group_id="O3" value="-0.72" lower_limit="-2.05" upper_limit="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.039</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>Constrained longitudinal data analysis</method>
            <method_desc>Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>-1.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.51</ci_lower_limit>
            <ci_upper_limit>-0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.669</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>Constrained longitudinal data analysis</method>
            <method_desc>Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.09</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 54 weeks (+/- 3 days)</time_frame>
      <desc>Data presented below include data following the initiation of rescue therapy for the entire study (ie, all data after randomization, with no upper limit on the follow-up window for participants who discontinued study drug).</desc>
      <group_list>
        <group group_id="E1">
          <title>Ertugliflozin 5 mg/Ertugliflozin 5 mg</title>
          <description>Phase A: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.</description>
        </group>
        <group group_id="E2">
          <title>Ertugliflozin 15 mg/Ertugliflozin 15 mg</title>
          <description>Phase A: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.</description>
        </group>
        <group group_id="E3">
          <title>Placebo/Metformin</title>
          <description>Phase A: Placebo to ertugliflozin administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Participants not rescued with open-label metformin in Phase A will also receive blinded metformin up to twice daily for 26 weeks in addition to placebo. Participants rescued with metformin in Phase A will continue to receive open-label metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Papilloedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Blindness transient</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Cellulitis of male external genital organ</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Periorbital abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the cervix</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Ruptured cerebral aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="156"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="152"/>
                <counts group_id="E3" events="26" subjects_affected="23" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E3" events="14" subjects_affected="12" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="152"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="156"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="152"/>
                <counts group_id="E3" events="15" subjects_affected="9" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="156"/>
                <counts group_id="E2" events="14" subjects_affected="10" subjects_at_risk="152"/>
                <counts group_id="E3" events="30" subjects_affected="19" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="156"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="152"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" events="14" subjects_affected="6" subjects_at_risk="152"/>
                <counts group_id="E3" events="23" subjects_affected="10" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="152"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Investigator will provide manuscripts, abstracts, or the full text of any other intended disclosure (poster presentation, invited speaker or guest lecturer presentation, etc.) to Sponsor at least 30 days before they are submitted for publication or otherwise disclosed. If any patent action is required to protect intellectual property rights, investigator agrees to delay the disclosure for a period not to exceed an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

